share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  May 11 04:04
Summary by Futu AI
Clearmind Medicine Inc., a clinical-stage biotech company, has announced significant advancements in its proprietary MEAI-based synthetic alcohol beverage program. The company has completed most pre-clinical studies required for novel-food application submissions, which are recognized in multiple jurisdictions globally. Clearmind has secured patents for its alcohol substitute in the U.S., India, and Europe. The initiative is spearheaded by Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada. CEO Dr. Adi Zuloff-Shani highlighted the product's alignment with the growing trend towards no- and low-alcohol consumption and its potential health benefits. The no/low alcohol market, valued at over $13 billion in 2023, is expected to grow at a CAGR of +6% from 2023 to 2027. Clearmind aims to commercialize its compounds as regulated medicines, foods, or supplements and holds a portfolio of 27 granted patents across 18 patent families. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced significant advancements in its proprietary MEAI-based synthetic alcohol beverage program. The company has completed most pre-clinical studies required for novel-food application submissions, which are recognized in multiple jurisdictions globally. Clearmind has secured patents for its alcohol substitute in the U.S., India, and Europe. The initiative is spearheaded by Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada. CEO Dr. Adi Zuloff-Shani highlighted the product's alignment with the growing trend towards no- and low-alcohol consumption and its potential health benefits. The no/low alcohol market, valued at over $13 billion in 2023, is expected to grow at a CAGR of +6% from 2023 to 2027. Clearmind aims to commercialize its compounds as regulated medicines, foods, or supplements and holds a portfolio of 27 granted patents across 18 patent families. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.